Homozygous LIPE mutation in siblings with multiple symmetric lipomatosis, partial lipodystrophy, and myopathy
GLP-1 inhibits glucagon release (which slows down the release of sugar into the blood so that you burn more fat), slows down gastric emptying (makes you feel full), and lowers the desire for food intake (because you feel full)
Cignas 2026 commercial formulary includes six GLP-1 medications: Wegovy (semaglutide for obesity and CVD), Zepbound (tirzepatide for obesity and OSA), Ozempic (semaglutide for type 2 diabetes), Mounjaro (tirzepatide for type 2 diabetes), Saxenda (liraglutide for obesity), and Rybelsus (oral semaglutide for type 2 diabetes)
Ipamorelin on the other hand will take quite a bit more explanation
No Human Pharmacokinetic Programme FDA found no pharmacokinetic data defining absorption, distribution, metabolism, half-life, clearance or tissue exposure for Epitalon free base or Epitalon acetate
Alternatively, integrins can alter their high- to low-affinity conformations, facilitating specific ligand binding (inside-out signaling) (Luo et al., 2007)
